Improve the prevention of sudden cardiac arrest in emerging countries

The Improve SCA clinical study design

Shu Zhang, Balbir Singh, Diego A. Rodriguez, Alexandr Robertovich Chasnoits, Azlan Hussin, Chi Keong Ching, Dejia Huang, Yen Bin Liu, Jeffrey Cerkvenik, Sarah Willey, Young Hoon Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized. Methods: Enrolment will consist of 4800 ICD-eligible patients from Asia, Latin America, Eastern Europe, the Middle East, and Africa. Upon enrolment, patients will be categorized as SP or PP. Primary prevention patients will be assessed for additional risk factors: syncope/pre-syncope, non-sustained ventricular tachycardia, frequent premature ventricular contractions, and low left ventricular ejection fraction. Those PP patients with one or more risk factors will be categorized as '1.5' patients. Implant of an ICD/CRT-D will be left to the patient and/or physician's discretion. The primary endpoint will compare the appropriate ICD therapy rate between SP and 1.5 patients. The secondary endpoint compares mortality between 1.5 implanted and non-implanted patients. Conclusion: The Improve SCA study will investigate a subset of PP patients, believed to be at similar risk of life-threatening ventricular arrhythmias as SP patients. Results may help clinicians identify and refer the highest risk PP patients for ICDs, help local societies expand guidelines to include PP of SCA utilizing ICDs, and provide additional geographical-relevant evidence to allow patients to make an informed decision whether to receive an ICD.

Original languageEnglish
Pages (from-to)1720-1726
Number of pages7
JournalEuropace
Volume17
Issue number11
DOIs
Publication statusPublished - 2015 Sep 28

Fingerprint

Sudden Cardiac Death
Primary Prevention
Implantable Defibrillators
Secondary Prevention
Cardiac Resynchronization Therapy
Defibrillators
Clinical Studies
Syncope
Cardiac Arrhythmias
Eastern Europe
Eastern Africa
Middle East
Ventricular Premature Complexes
Latin America
Ventricular Tachycardia
Stroke Volume

Keywords

  • LVEF
  • NSVT
  • Primary prevention
  • PVCs
  • SCA
  • Secondary prevention
  • Syncope

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Zhang, S., Singh, B., Rodriguez, D. A., Chasnoits, A. R., Hussin, A., Ching, C. K., ... Kim, Y. H. (2015). Improve the prevention of sudden cardiac arrest in emerging countries: The Improve SCA clinical study design. Europace, 17(11), 1720-1726. https://doi.org/10.1093/europace/euv103

Improve the prevention of sudden cardiac arrest in emerging countries : The Improve SCA clinical study design. / Zhang, Shu; Singh, Balbir; Rodriguez, Diego A.; Chasnoits, Alexandr Robertovich; Hussin, Azlan; Ching, Chi Keong; Huang, Dejia; Liu, Yen Bin; Cerkvenik, Jeffrey; Willey, Sarah; Kim, Young Hoon.

In: Europace, Vol. 17, No. 11, 28.09.2015, p. 1720-1726.

Research output: Contribution to journalArticle

Zhang, S, Singh, B, Rodriguez, DA, Chasnoits, AR, Hussin, A, Ching, CK, Huang, D, Liu, YB, Cerkvenik, J, Willey, S & Kim, YH 2015, 'Improve the prevention of sudden cardiac arrest in emerging countries: The Improve SCA clinical study design', Europace, vol. 17, no. 11, pp. 1720-1726. https://doi.org/10.1093/europace/euv103
Zhang S, Singh B, Rodriguez DA, Chasnoits AR, Hussin A, Ching CK et al. Improve the prevention of sudden cardiac arrest in emerging countries: The Improve SCA clinical study design. Europace. 2015 Sep 28;17(11):1720-1726. https://doi.org/10.1093/europace/euv103
Zhang, Shu ; Singh, Balbir ; Rodriguez, Diego A. ; Chasnoits, Alexandr Robertovich ; Hussin, Azlan ; Ching, Chi Keong ; Huang, Dejia ; Liu, Yen Bin ; Cerkvenik, Jeffrey ; Willey, Sarah ; Kim, Young Hoon. / Improve the prevention of sudden cardiac arrest in emerging countries : The Improve SCA clinical study design. In: Europace. 2015 ; Vol. 17, No. 11. pp. 1720-1726.
@article{e6253b681c4144789ec324bebbf7dfbb,
title = "Improve the prevention of sudden cardiac arrest in emerging countries: The Improve SCA clinical study design",
abstract = "Aims: This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized. Methods: Enrolment will consist of 4800 ICD-eligible patients from Asia, Latin America, Eastern Europe, the Middle East, and Africa. Upon enrolment, patients will be categorized as SP or PP. Primary prevention patients will be assessed for additional risk factors: syncope/pre-syncope, non-sustained ventricular tachycardia, frequent premature ventricular contractions, and low left ventricular ejection fraction. Those PP patients with one or more risk factors will be categorized as '1.5' patients. Implant of an ICD/CRT-D will be left to the patient and/or physician's discretion. The primary endpoint will compare the appropriate ICD therapy rate between SP and 1.5 patients. The secondary endpoint compares mortality between 1.5 implanted and non-implanted patients. Conclusion: The Improve SCA study will investigate a subset of PP patients, believed to be at similar risk of life-threatening ventricular arrhythmias as SP patients. Results may help clinicians identify and refer the highest risk PP patients for ICDs, help local societies expand guidelines to include PP of SCA utilizing ICDs, and provide additional geographical-relevant evidence to allow patients to make an informed decision whether to receive an ICD.",
keywords = "LVEF, NSVT, Primary prevention, PVCs, SCA, Secondary prevention, Syncope",
author = "Shu Zhang and Balbir Singh and Rodriguez, {Diego A.} and Chasnoits, {Alexandr Robertovich} and Azlan Hussin and Ching, {Chi Keong} and Dejia Huang and Liu, {Yen Bin} and Jeffrey Cerkvenik and Sarah Willey and Kim, {Young Hoon}",
year = "2015",
month = "9",
day = "28",
doi = "10.1093/europace/euv103",
language = "English",
volume = "17",
pages = "1720--1726",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Improve the prevention of sudden cardiac arrest in emerging countries

T2 - The Improve SCA clinical study design

AU - Zhang, Shu

AU - Singh, Balbir

AU - Rodriguez, Diego A.

AU - Chasnoits, Alexandr Robertovich

AU - Hussin, Azlan

AU - Ching, Chi Keong

AU - Huang, Dejia

AU - Liu, Yen Bin

AU - Cerkvenik, Jeffrey

AU - Willey, Sarah

AU - Kim, Young Hoon

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Aims: This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized. Methods: Enrolment will consist of 4800 ICD-eligible patients from Asia, Latin America, Eastern Europe, the Middle East, and Africa. Upon enrolment, patients will be categorized as SP or PP. Primary prevention patients will be assessed for additional risk factors: syncope/pre-syncope, non-sustained ventricular tachycardia, frequent premature ventricular contractions, and low left ventricular ejection fraction. Those PP patients with one or more risk factors will be categorized as '1.5' patients. Implant of an ICD/CRT-D will be left to the patient and/or physician's discretion. The primary endpoint will compare the appropriate ICD therapy rate between SP and 1.5 patients. The secondary endpoint compares mortality between 1.5 implanted and non-implanted patients. Conclusion: The Improve SCA study will investigate a subset of PP patients, believed to be at similar risk of life-threatening ventricular arrhythmias as SP patients. Results may help clinicians identify and refer the highest risk PP patients for ICDs, help local societies expand guidelines to include PP of SCA utilizing ICDs, and provide additional geographical-relevant evidence to allow patients to make an informed decision whether to receive an ICD.

AB - Aims: This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized. Methods: Enrolment will consist of 4800 ICD-eligible patients from Asia, Latin America, Eastern Europe, the Middle East, and Africa. Upon enrolment, patients will be categorized as SP or PP. Primary prevention patients will be assessed for additional risk factors: syncope/pre-syncope, non-sustained ventricular tachycardia, frequent premature ventricular contractions, and low left ventricular ejection fraction. Those PP patients with one or more risk factors will be categorized as '1.5' patients. Implant of an ICD/CRT-D will be left to the patient and/or physician's discretion. The primary endpoint will compare the appropriate ICD therapy rate between SP and 1.5 patients. The secondary endpoint compares mortality between 1.5 implanted and non-implanted patients. Conclusion: The Improve SCA study will investigate a subset of PP patients, believed to be at similar risk of life-threatening ventricular arrhythmias as SP patients. Results may help clinicians identify and refer the highest risk PP patients for ICDs, help local societies expand guidelines to include PP of SCA utilizing ICDs, and provide additional geographical-relevant evidence to allow patients to make an informed decision whether to receive an ICD.

KW - LVEF

KW - NSVT

KW - Primary prevention

KW - PVCs

KW - SCA

KW - Secondary prevention

KW - Syncope

UR - http://www.scopus.com/inward/record.url?scp=84950311843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950311843&partnerID=8YFLogxK

U2 - 10.1093/europace/euv103

DO - 10.1093/europace/euv103

M3 - Article

VL - 17

SP - 1720

EP - 1726

JO - Europace

JF - Europace

SN - 1099-5129

IS - 11

ER -